Open | 2.76 |
Previous Close | 2.76 |
Volume | 819.9 Thou. |
Average Volume | 1.4 Mil. |
Day's Range | 2.76 โ 2.94 |
52 Week Range | 1.575-5.02 |
Market Cap | 456.3 Mil. |
Moving Average (50) | 2.5318 |
Moving Average (200) | 3.13203 |
Earnings per Share (EPS) | -0.35 |
Price/Earnings (PE) | -8.2 |
Shares Outstanding | 159 Mil. |
Earnings Date | Aug 11, 2025 |
Beta | 0.345 |
Last Dividend | 0 |
MREO Latest News
|
|
|
|
|
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
About Mereo BioPharma Group | |
Industry | Biotechnology |
Sector | Healthcare |
Number of Employees | 36 |
Website & Executive | |
Website | https://www.mereobiopharma.com |
CEO (Chief Executive Officer) | Denise Vera Scots-Knight |
IPO date | 2019-04-24 |
Contact | |
Country | GB |
Address | One Cavendish Place |
City | London |
State | None |
Phone | 44 33 3023 7300 |
Zip Code | W1G 0QF |
Other Identifiers | |
CIK | 0001719714 |
ISIN | US5894921072 |
CUSIP | 589492107 |